Featured Research

from universities, journals, and other organizations

Adolescent smokers have artery damage

Date:
August 25, 2012
Source:
European Society of Cardiology (ESC)
Summary:
Early exposure to tobacco smoke is associated with various adverse health outcomes in children and adolescents, including low birth weight and impaired lung growth and function. Tobacco smoke is considered highly atherogenic in adults, but little is known about the impact of tobacco smoke exposure on cardiovascular health in adolescents. Children and adolescents are exposed to tobacco smoke through passive and active smoking.

Early exposure to tobacco smoke is associated with various adverse health outcomes in children and adolescents, including low birth weight and impaired lung growth and function. Tobacco smoke is considered highly atherogenic in adults, but little is known about the impact of tobacco smoke exposure on cardiovascular health in adolescents. Children and adolescents are exposed to tobacco smoke through passive and active smoking.

Atherosclerosis is a multi-factorial disease which begins in childhood and in utero. Tobacco smoke exerts its effects through toxic compounds which cross the placental barrier and alveolar wall of the lungs. This leads to increased local and systemic inflammation.

The Swiss Study on Air Pollution And Lung and Heart Disease In Adults (SAPALDIA) is a multicentre study of nearly 10,000 subjects. The SAPALDIA Youth Study included 351 offspring of SAPALDIA participants aged 8 -20 years. It investigated the cardiovascular risk profile and the association between active smoking and carotid artery intima-media thickness (CIMT), an early indicator of atherosclerotic changes in the vessel wall.

For the current study presented at the ESC Congress, 288 of the offspring underwent a clinical examination following a standardized protocol: anthropometry, blood pressure, ultrasound CIMT assessment, and blood tests for cardiovascular biomarkers. Subjects reported their level of physical activity, smoking status and exposure to passive smoking. Cotinine testing was used to validate smoking status and exposure to passive smoke.

Regular current smoking (daily/weekly) was reported by 11% of the 288 offspring (mean age 15 years; 53% girls) and by 15% when including less frequent smokers (monthly). Mean smoking duration was 2.3+1.98 years in ever-smokers. Exposure to passive smoke up to 10 years of age was reported by 31% of subjects and current parental smoking by 25%. Three per cent of adolescents were obese, 13% overweight and 60% reported less than 4 hours of either strenuous or moderate activity per week. Parental history of cardiovascular disease or cardiovascular risk factors were present in 22% of the participants.

CIMT is an accepted indicator of atherosclerosis in all age groups. In this study the mean CIMT in all subjects was 0.50+0.08mm. Multivariate regression analyses showed a significant effect of regular current smoking, with an increase in CIMT of 0.043mm (95%CI=0.014-0.073). "The results remained consistent when adjusting additionally for parental smoking, which means that the association observed was not confounded by parental smoking," said Dr Dratva. "Smoking duration was positively associated with CIMT, showing that the longer subjects smoked, the greater their carotid artery intima-media thickness." The independent role of passive smoking on the artery wall in childhood is currently being investigated in the SAPALDIA Youth Study.

She added: "Our study in adolescents addresses important early risk factors of cardiovascular health in adolescents. After a relatively short duration of active smoking, the vascular structure already shows signs of structural changes, compared to non-smoking adolescents. These results give evidence of an early adverse impact of active tobacco exposure on the vasculature, which is indicative of early development of atherosclerosis."

Dr Dratva continued: "Urgent action is needed to help adolescent smokers kick the habit and stop others from taking up smoking. More research is required to determine whether the damage to the vascular structure of smoking adolescents is reversible if they quit smoking."


Story Source:

The above story is based on materials provided by European Society of Cardiology (ESC). Note: Materials may be edited for content and length.


Cite This Page:

European Society of Cardiology (ESC). "Adolescent smokers have artery damage." ScienceDaily. ScienceDaily, 25 August 2012. <www.sciencedaily.com/releases/2012/08/120825155654.htm>.
European Society of Cardiology (ESC). (2012, August 25). Adolescent smokers have artery damage. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2012/08/120825155654.htm
European Society of Cardiology (ESC). "Adolescent smokers have artery damage." ScienceDaily. www.sciencedaily.com/releases/2012/08/120825155654.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins